Hyponatremia as a predictor for worsening heart failure in patients receiving cardiac resynchronization therapy

Circulation Journal

Volumn 77, Issue 1, 2013, Pages 116-122

  Arao, Kenshiro ^a   Fujiwara, Takayuki ^a   Sakakura, Kenichi ^a   Wada, Hiroshi ^a   Sugawara, Yoshitaka ^a   Suga, Chikashi ^a   Ako, Junya ^a   Ishikawa, San e ^a   Momomura, Shin ichi ^a  

^a JICHI MEDICAL UNIVERSITY   (Japan)

Author keywords

Cardiac resynchronization therapy; Chronic heart failure; Prognosis; Sodium

Indexed keywords

ARGIPRESSIN; SODIUM;

ADULT; AGED; ARTICLE; BLOOD CHEMISTRY; CARDIAC RESYNCHRONIZATION THERAPY; CARDIOVASCULAR RISK; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAPHY; FEMALE; FOLLOW UP; HEART CATHETERIZATION; HEART FAILURE; HUMAN; HYPONATREMIA; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PROPORTIONAL HAZARDS MODEL;

AGED; ARGININE VASOPRESSIN; CARDIAC RESYNCHRONIZATION THERAPY; FEMALE; FOLLOW-UP STUDIES; HEART FAILURE; HUMANS; HYPONATREMIA; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; RISK FACTORS; SODIUM;

EID: 84871685310     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-12-0672     Document Type: Article

References (31)

1. Shiba N, Shimokawa H. Chronic heart failure in Japan: Implications of the CHART studies. Vasc Health Risk Manag 2008; 4: 103-113
2. Gheorghiade M, Abraham WT, Albert NM, Gattis-Stough W, Greenberg BH, O'Connor CM, et al; OPTIMIZE-HF Investigators and Coordinators. Relationship between admission serum sodium concentration and clinical outcomes in patients hospitalized for heart failure: An analysis from the OPTIMIZE-HF registry. Eur Heart J 2007; 28: 980-988
3. Klein L, O'Connor CM, Leimberger JD, Gattis-Stough W, Piña IL, Felker GM, et al; OPTIME-CHF Investigators. Lower serum sodium is associated with increased short-term mortality in hospitalized patients with worsening heart failure: Results from the Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure (OPTIME-CHF) study. Circulation 2005; 111: 2454-2460
4. Gheorghiade M, Rossi JS, Cotts W, Shin DD, Hellkamp AS, Piña IL, et al. Characterization and prognostic value of persistent hyponatremia in patients with severe heart failure in the ESCAPE Trial. Arch Intern Med 2007; 167: 1998-2005
5. Aaronson KD, Schwartz JS, Chen TM, Wong KL, Goin JE, Mancini DM. Development and prospective validation of a clinical index to predict survival in ambulatory patients referred for cardiac transplant evaluation. Circulation 1997; 95: 2660-2667
6. Levy WC, Mozaffarian D, Linker DT, Farrar DJ, Miller LW; REMATCH Investigators. Can the Seattle heart failure model be used to risk-stratify heart failure patients for potential left ventricular assist device therapy? J Heart Lung Transplant 2009; 28: 231-236
7. Abraham WT, Fisher WG, Smith AL, Delurgio DB, Leon AR, Loh E, et al; MIRACLE Study Group. Multicenter InSync Randomized Clinical Evaluation. N Engl J Med 2002; 346: 1845-1853
8. Swedberg K, Cleland J, Dargie H, Drexler H, Follath F, Komajda M, et al; Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. Guidelines for the diagnosis and treatment of chronic heart failure: Executive summary (update 2005): The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. Eur Heart J 2005; 26: 1115-1140
9. Duncan A, Wait D, Gibson D, Daubert JC; MUSTIC (Multisite Stimulation in Cardiomyopathies) Trial. Left ventricular remodelling and haemodynamic effects of multisite biventricular pacing in patients with left ventricular systolic dysfunction and activation disturbances in sinus rhythm: Sub-study of the MUSTIC (Multisite Stimulation In Cardiomyopathies) trial. Eur Heart J 2003; 24: 430-441
10. Bristow MR, Saxon LA, Boehmer J, Krueger S, Kass DA, De Marco T, et al; Comparison of Medical Therapy, Pacing, and Defibrillation in Heart Failure (COMPANION) Investigators. Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med 2004; 350: 2140-2150
11. Cleland JG, Daubert JC, Erdmann E, Freemantle N, Gras D, Kappenberger L, et al; Cardiac Resynchronization-Heart Failure (CARE-HF) Study Investigators. The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med 2005; 352: 1539-1549
12. Momomura S, Tsutsui H, Sugawara Y, Ito M, Mitsuhashi T, Fukamizu S, et al; for the MOMIJI Study Investigators. Clinical efficacy of cardiac resynchronization therapy with an implantable defibrillator in a Japanese population: Results of the MIRACLE-ICD Outcome Measured in Japanese Indication (MOMIJI) Study. Circ J 2012; 76: 1911-1919
13. Iaina A, Silverberg DS, Wexler D. Therapy insight: Congestive heart failure, chronic kidney disease and anemia, the cardio-renal-anemia syndrome. Nat Clin Pract Cardiovasc Med 2005; 2: 95-100
14. Auricchio A, Prinzen FW. Non-responders to cardiac resynchronization therapy: The magnitude of the problem and the issues [Review]. Circ J 2011; 75: 521-527
15. Cazeau S, Leclercq C, Lavergne T, Walker S, Varma C, Linde C, et al; Multisite Stimulation in Cardiomyopathies (MUSTIC) Study Investigators. Effects of multisite biventricular pacing in patients with heart failure and intraventricular conduction delay. N Engl J Med 2001; 344: 873-880
16. Leclercq C, Walker S, Linde C, Clementy J, Marshall AJ, Ritter P, et al. Comparative effects of permanent biventricular and right-univentricular pacing in heart failure patients with chronic atrial fibrillation. Eur Heart J 2002; 23: 1780-1787
17. Strik M, Ploux S, Vernooy K, Prinzen FW. Cardiac resynchronization therapy: Refocus on the electrical substrate. Circ J 2011; 75: 1297-1304
18. Soliman OI, Geleijnse ML, Theuns DA, van Dalen BM, Vletter WB, Jordaens LJ, et al. Usefulness of left ventricular systolic dyssynchrony by real-time three-dimensional echocardiography to predict long-term response to cardiac resynchronization therapy. Am J Cardiol 2009; 103: 1586-1591
19. Yu CM, Wing-Hong Fung J, Zhang Q, Sanderson JE. Understanding nonresponders of cardiac resynchronization therapy-current and future perspectives. J Cardiovasc Electrophysiol 2005; 16: 1117-1124
20. Daubert C, Gold MR, Abraham WT, Ghio S, Hassager C, Goode G, et al; REVERSE Study Group. Prevention of disease progression by cardiac resynchronization therapy in patients with asymptomatic or mildly symptomatic left ventricular dysfunction: Insights from the European cohort of the REVERSE (Resynchronization Reverses Remodeling in Systolic Left Ventricular Dysfunction) trial. J Am Coll Cardiol 2009; 54: 1837-1846
21. Arao K, Yasu T, Ohmura N, Tsukamoto Y, Murata M, Kubo N, et al. Circulating CD34+/133+ progenitor cells in patients with stable angina pectoris undergoing percutaneous coronary intervention. Circ J 2010; 74: 1929-1935
22. Chung ES, Leon AR, Tavazzi L, Sun JP, Nihoyannopoulos P, Merlino J, et al. Results of the Predictors of Response to CRT (PROSPECT) trial. Circulation 2008; 117: 2608-2616
23. Wang NC, Maggioni AP, Konstam MA, Zannad F, Krasa HB, Burnett JC Jr, et al; Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study With Tolvaptan (EVEREST) Investigators. Clinical implications of QRS duration in patients hospitalized with worsening heart failure and reduced left ventricular ejection fraction. JAMA 2008; 299: 2656-2666
24. Funayama H, Nakamura T, Saito T, Yoshimura A, Saito M, Kawakami M, et al. Urinary excretion of aquaporin-2 water channel exaggerated dependent upon vasopressin in congestive heart failure. Kidney Int 2004; 66: 1387-1392
25. Schrier RW, Berl T, Anderson RJ. Osmotic and nonosmotic control of vasopressin release. Am J Physiol 1979; 236: F321-F332
26. Schrier RW. Pathogenesis of sodium and water retention in highoutput and low-output cardiac failure, nephrotic syndrome, cirrhosis, and pregnancy. N Engl J Med 1988; 319: 1065-1072
27. Szatalowicz VL, Arnold PE, Chaimovitz C, Bichet D, Berl T, Schrier RW. Radioimmunoassay of plasma arginine vasopressin in hyponatremic patients with congestive heart failure. N Engl J Med 1981; 305: 263-266
28. Schrier RW, Gross P, Gheorghiade M, Berl T, Verbalis JG, Czerwiec FS, et al; SALT Investigators. Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia. N Engl J Med 2006; 355: 2099-2112
29. Gheorghiade M, Gattis WA, O'Connor CM, Adams KF Jr, Elkayam U, Barbagelata A, et al; Acute and Chronic Therapeutic Impact of a Vasopressin Antagonist in Congestive Heart Failure (ACTIV in CHF) Investigators. Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: A randomized controlled trial. JAMA 2004; 291: 1963-1971
30. Gheorghiade M, Konstam MA, Burnett JC Jr, Grinfeld L, Maggioni AP, Swedberg K, et al; Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study With Tolvaptan (EVEREST) Investigators. Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: The EVEREST Clinical Status Trials. JAMA 2007; 297: 1332-1343
31. Tolvaptan for Treatment of Hypervolemic and Euvolemic Hyponatremia. Cardiovascular and Renal Drug Advisory Committee Meeting. Otsuka Pharmaceutical Development & Commercialization, Inc. Core presentation and Backup Files 2008:143 [http://www.fda.gov/ ohrms/dockets/ac/08/slides/2008-4373s1-00-index.htm] (accessed April 12, 2012).